Multiple Myeloma Clinical Trials

167 studies are recruiting for multiple myeloma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 5

1. FAST-M: Prolonged Overnight Fasting and Mediterranean Dietary Intervention for Patients With Multiple Myeloma or Its Precursor Disease

   The purpose of this study is to find out whether a dietary approach that includes prolonged overnight fasting, guided by a Mediterranean-style eating pattern, is feasible for patients with myeloma precursor disease or newly diagnosed multiple myeloma.

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of Miami, Miami, Florida

   Run by

   University of Miami

   See if you can join NCT07446777 on ClinicalTrials.gov

2. A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant

   The purpose of this study is to see if siltuximab plus population pharmacokinetic (PK)-dosed melphalan works as well as the usual approach (body surface area [BSA]-dosed melphalan) in people with multiple myeloma (MM) who are receiving an autologous stem cell transplant (ASCT) as part of their stan…

   Stage

   Phase 2

   Ages

   60 and older

   Site

   Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey

   Locations

   7 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT06679829 on ClinicalTrials.gov

3. Post-Op Pain Control for Prophylactic Intramedullary Nailing.

   Nationally, the opioid crisis has become a major epidemic with increasing mortality rates each year. Orthopedic surgeons routinely prescribe narcotics instead of NSAIDs for post-op pain control because of risk of delayed healing and nonunion due to NSAID use. Orthopedic oncology, however, has a uni…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Saint Louis University, St Louis, Missouri

   Run by

   St. Louis University

   See if you can join NCT03823534 on ClinicalTrials.gov

4. Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

   This is a phase II study to evaluate the outpatient administration of Teclistamab or Talquetamab in Multiple Myeloma patients

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Arizona Oncology Associates, Tucson, Arizona

   Locations

   17 in total

   Run by

   SCRI Development Innovations, LLC

   See if you can join NCT05972135 on ClinicalTrials.gov

5. A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

   The purpose of this Phase 3 study is to evaluate if BRd prolongs progression free survival (PFS) and/or improves minimal residual disease (MRD) negative status compared with DRd in participants with TI-NDMM.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   GSK Investigational Site, Mobile, Alabama

   Locations

   181 in total

   Run by

   GlaxoSmithKline

   See if you can join NCT06679101 on ClinicalTrials.gov

6. Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy

   The goal of this study is to determine whether a palliative care intervention (PEACE) can improve the quality of life and experiences of participants with Lymphoma, Leukemia, or Multiple Myeloma receiving adoptive cellular therapy (ACT). After completion of an open pilot, participants will be rando…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Massachusetts General Hospital Cancer Center, Boston, Massachusetts

   Run by

   Massachusetts General Hospital

   See if you can join NCT05646576 on ClinicalTrials.gov

7. Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma

   The main purpose of this study is to learn about the safety of linvoseltamab and to find out what is the best dose of linvoseltamab to give to patients with multiple myeloma and to look for any signs that linvoseltamab can effectively treat cancer. The study is looking at several other research que…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Moffitt Cancer Center - McKinley Drive, Tampa, Florida

   Locations

   40 in total

   Run by

   Regeneron Pharmaceuticals

   See if you can join NCT03761108 on ClinicalTrials.gov

8. CAR T-cell Therapy in Patients With Renal Dysfunction

   This is a prospective, descriptive study designed to assess the feasibility of administering CAR T therapy among patients with moderate to severe renal impairment using dose adjusted lymphodepleting chemotherapy.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Caitlin Guzowski, Atlanta, Georgia

   Run by

   Northside Hospital, Inc.

   See if you can join NCT05909059 on ClinicalTrials.gov

9. At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

   This clinical trial studies the effect of cancer directed therapy given at-home versus in the clinic for patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Currently most drug-related cancer care is conducted…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Mayo Clinic in Florida, Jacksonville, Florida

   Locations

   2 in total

   Run by

   Mayo Clinic

   See if you can join NCT05969860 on ClinicalTrials.gov

10. Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma

    This study is a Phase II study to determine the preliminary safety and efficacy of salvage radiation treatment after BCMA CAR-T therapy in subjects with RRMM. The study population will consist of subjects with RRMM previously treated with SOC BCMA CAR-T cell therapy with active disease on the D30+ …

    Stage

    Phase 2

    Ages

    18 and older

    Site

    M D Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT05336383 on ClinicalTrials.gov

11. The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen

    To provide the IRB approved mechanism for the prospective collection and analysis on participants who are undergoing either an autologous or allogeneic hematopoietic stem cell transplant for a disease in which a research question is not being addressed.

    Stage

    Not phased

    Ages

    18 to 120

    Site

    Wake Forest Baptist Health, Winston-Salem, North Carolina

    Run by

    Wake Forest University Health Sciences

    See if you can join NCT01890486 on ClinicalTrials.gov

12. Remote Monitoring With Health-Coaching to Improve Quality of Life in Older Patients With Multiple Myeloma

    This clinical trial tests the effectiveness of a home-based mindfulness physical activity program with remote monitoring combined with structured telephone-based health coaching to decrease fatigue and improve quality of life in older patients with multiple myeloma (MM). Studies have shown that MM …

    Stage

    Not phased

    Ages

    65 and older

    Site

    Mayo Clinic in Rochester, Rochester, Minnesota

    Run by

    Mayo Clinic

    See if you can join NCT06145581 on ClinicalTrials.gov

13. Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions

    The key aim of the study is to define the two biologically and clinically distinct entities: progressive versus stable myeloma precursor conditions.

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of Miami Hospitals, Miami, Florida

    Run by

    University of Miami

    See if you can join NCT05361694 on ClinicalTrials.gov

14. Study of CAR-T Therapy in Older Patients

    This study is being done to find out how older patients respond to CAR-T cell therapy and how the treatment affects their quality of life. This is a quality of life study and participating in the study does not involve receiving any treatment, other than the standard treatment for participants' dis…

    Stage

    Not phased

    Ages

    60 and older

    Site

    Memorial Sloan Kettering Cancer Center, New York, New York

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT04300998 on ClinicalTrials.gov

15. Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma

    This phase I trial studies the safety, side effects, best dose and effectiveness of mezigdomide (CC-92480) when given after idecabtagene vicleucel (Abecma chimeric antigen receptor [CAR] T-cell therapy) in patients with multiple myeloma that has come back after a period of improvement (relapsed). C…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    City of Hope Medical Center, Duarte, California

    Run by

    City of Hope Medical Center

    See if you can join NCT06048250 on ClinicalTrials.gov

16. ATRA and Carfilzomib in Plasma Cell Myeloma Patients

    This is a Phase IB/II trial that will investigate the safety, tolerability and efficacy of combination therapy using All-Trans Retinoic Acid (ATRA) with Carfilzomib based therapies in plasma cell myeloma also commonly referred as Multiple Myeloma (MM), in patients considered refractory to proteasom…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Houston Methodist Neal Cancer Center, Houston, Texas

    Run by

    The Methodist Hospital Research Institute

    See if you can join NCT06536413 on ClinicalTrials.gov

17. Hypofractionation (Radiation) Trial for Multiple Myeloma

    This study if for people who have been diagnosed with multiple myeloma and their doctors are recommending radiation to help treat it. Typically, radiation consists of 2-3 weeks of external beam radiation therapy. Doctors leading this study would like to see if a shorter radiation course (i.e., hypo…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The University of Chicago Comprehensive Cancer Center, Chicago, Illinois

    Run by

    University of Chicago

    See if you can join NCT06270888 on ClinicalTrials.gov

18. A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

    A phase 1/2 dose escalation / dose expansion study of Enzomenib (DSP-5336) in patients with acute leukemia.

    Stage

    Phase 1

    Ages

    12 and older

    Site

    Hoag Family Cancer Center, Newport Beach, California

    Locations

    104 in total

    Run by

    Sumitomo Pharma America, Inc.

    See if you can join NCT04988555 on ClinicalTrials.gov

19. Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource

    The investigators are researching patients with diseases of their plasma cells in order to improve their quality and length of life. The investigators have created a database of patient information, blood samples, and bone marrow tissue in order to achieve the following three goals: * Surveillance:…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Ohio State University Medical Center, Columbus, Ohio

    Run by

    Ohio State University Comprehensive Cancer Center

    See if you can join NCT01408225 on ClinicalTrials.gov

20. Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma

    This phase I trial will evaluate the safety, side effects, and best dose of talquetamab in combination with iberdomide and dexamethasone in treating patients with multiple myeloma that has come back after a period of improvement (relapsed) or has not responded to previous treatment (refractory). Th…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Calfornia, San Francisco, San Francisco, California

    Run by

    Alfred Chung, MD

    See if you can join NCT06348108 on ClinicalTrials.gov

21. Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure

    The goal of this study is to assess the efficacy of induction treatment with daratumumab-hyaluronidase (dara SC) with cyclophosphamide, bortezomib, and dexamethasone (Dara-CyBorD) for four cycles in patients with newly diagnosed multiple myeloma who have new onset renal failure. This study will als…

    Stage

    EARLY_Phase 1

    Ages

    18 to 80

    Site

    Georgia Cancer Center-Augusta University, Augusta, Georgia

    Run by

    Augusta University

    See if you can join NCT06142396 on ClinicalTrials.gov

22. Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function

    Treatment for relapsed/refractory multiple myeloma continues to evolve with the approval of highly effective anti-BCMA CAR T therapies in recent years. However, despite the high prevalence of renal insufficiency in this population, pivotal clinical trials have excluded patients with impaired renal …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Washington University School of Medicine, St Louis, Missouri

    Run by

    Washington University School of Medicine

    See if you can join NCT06623630 on ClinicalTrials.gov

23. A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy

    The researchers are doing this study to find out whether talquetamab is an effective treatment after BCMA CAR Tcell therapy for people with relapsed or refractory multiple myeloma. All participants in this study will have already received the BCMA CAR T-cell therapy ide-cel for their disease.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey

    Locations

    7 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT06066346 on ClinicalTrials.gov

24. Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring

    The goal of this study is to create a data set to add to Carevive's registry from real world clinical and patient reported data collected using an electronic care planning system (CPS) with remote symptom monitoring that is used in routine care for cancer patients on active treatment. Patients will…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Northshore University Health System, Evanston, Illinois

    Locations

    7 in total

    Run by

    Carevive Systems, Inc.

    See if you can join NCT05974150 on ClinicalTrials.gov

25. Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)

    The purpose of this study is to see whether combination treatment of Teclistamab and Daratumumab (Tel-Dara) or combination Talquetamab and Daratumumab (Tal-Dara) will delay the onset of multiple myeloma.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of Miami, Miami, Florida

    Run by

    Carl Ola Landgren, MD, PhD

    See if you can join NCT06100237 on ClinicalTrials.gov